Winlevi is not a corticosteroid, and it does not work like one. It is an androgen receptor inhibitor, a drug that blocks the effects of hormones called androgens in the skin. That said, clascoterone (the active ingredient in Winlevi) does have a steroid-like chemical structure, which is where the confusion comes from. Its four-ring molecular backbone is identical to dihydrotestosterone (DHT), the androgen that drives acne, and to spironolactone, an older anti-androgen medication. But sharing a chemical skeleton with steroid hormones does not make Winlevi a corticosteroid in the way most people mean when they ask the question.
Why Winlevi Gets Confused With Steroids
In chemistry, “steroid” refers to any molecule built on a specific four-ring carbon structure. Testosterone, estrogen, cortisol, cholesterol, and even some plant compounds are all technically steroids by this definition. Clascoterone sits in this broad chemical family. Some scientific literature even describes it as a “steroidal topical androgen receptor inhibitor” because of that backbone.
But when most people ask “is this a steroid?” they’re really asking whether a drug is a corticosteroid, the class of anti-inflammatory medications (like hydrocortisone or prednisone) known for side effects such as skin thinning, rebound flares, and immune suppression. Winlevi is not in that category. It does not suppress inflammation the way corticosteroids do, and it is not prescribed for the same reasons.
How Winlevi Actually Works
Winlevi targets androgen receptors in the skin. Androgens like testosterone and DHT bind to receptors in your sebaceous (oil) glands and hair follicles, ramping up oil production and fueling acne. Clascoterone competes with those hormones for the same receptor. Because its shape closely mimics DHT, it fits into the receptor and blocks the real hormone from attaching, which reduces the downstream signaling that triggers breakouts.
This makes Winlevi the first topical androgen blocker approved for acne, and notably the first androgen blocker that can be used in males. Older anti-androgen options like spironolactone are taken as pills and prescribed almost exclusively to women because of their systemic hormonal effects. Winlevi works locally in the skin, which sidesteps most of those whole-body concerns.
FDA Approval and Who Can Use It
The FDA approved Winlevi in August 2020 for the topical treatment of acne vulgaris in patients 12 years of age and older. It is applied as a thin layer of 1% cream to affected areas twice daily. It represents the first new mechanism of action for acne treatment in decades, since most existing options work by killing bacteria, unclogging pores, or reducing inflammation rather than addressing the hormonal component directly on the skin.
One Steroid-Related Concern to Know About
Although Winlevi is not a corticosteroid, it does have one side effect that overlaps with corticosteroid territory: it can temporarily suppress your body’s cortisol production system, known as the HPA axis. In clinical studies, this occurred in about 5% of adult subjects and 9% of adolescents after two weeks of twice-daily use. The suppression was mild and fully reversed within four weeks of stopping treatment.
This happens because clascoterone’s main breakdown product in the body is cortexolone, a naturally occurring but inactive precursor to cortisol. When enough of the drug absorbs through the skin, that metabolite can briefly interfere with normal cortisol signaling. The risk increases with use over large surface areas, prolonged application, or covering treated skin with bandages or occlusive dressings. Adolescents may be slightly more susceptible than adults.
This effect is worth understanding, but it is not the same as using a topical corticosteroid. Corticosteroids actively deliver anti-inflammatory steroids to the skin and carry risks like thinning, stretch marks, and worsening acne with long-term use. Winlevi’s HPA suppression is an incidental pharmacological effect, not the drug’s intended action.
How Winlevi Compares to Other Acne Treatments
Most topical acne treatments fall into a few categories: retinoids (which speed up skin cell turnover), benzoyl peroxide (which kills acne-causing bacteria), and antibiotics (which also target bacteria). Winlevi works through none of these pathways. It addresses the hormonal trigger directly at the skin level, which makes it a genuinely different tool, especially for people whose acne is clearly driven by oil overproduction and hormonal fluctuations.
Spironolactone is the closest comparison in terms of mechanism, since it also blocks androgen receptors. But spironolactone is an oral medication with systemic effects on blood pressure, potassium levels, and hormones throughout the body. It is generally not prescribed to men or adolescent boys because it can cause breast tissue growth and other feminizing effects. Winlevi avoids these issues by staying largely in the skin. Its chemical structure shares the same four-ring backbone as spironolactone, but the topical delivery keeps its activity local.
For people who have tried standard acne treatments without success, or whose acne has a clear hormonal pattern, Winlevi offers an option that works through a completely different mechanism without the systemic trade-offs of oral anti-androgens.